Search clinical trials for: BIA 9-1067 15 mg

Total 786 results

Bial - Portela C S.A.

Completed

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone

Parkinson Disease
Bial - Portela C S.A.

Completed

Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers

Parkinson
Galderma R&D

Completed

Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma

Basal Cell Carcinoma

United States
N-Gene Research Laboratories, Inc.
Thermo Fisher Scientific, Inc; Integrium; Msource Medical Development GmbH; Kinexum... and other collaborators

Terminated

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States, Germany, Hungary
Pfizer

Terminated

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)

Chronic Cough

Canada, Czechia, Denmark, Hungary, Peru, Poland, Ukraine, United Kingdom, United States, Australia, China, Colombia, Germany, Guatemala, Israel, Italy, Malaysia, New Zealand, South Africa, Turkey
Merck Sharp & Dohme LLC

Completed

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension

Chronic Cough

China
Bial - Portela C S.A.

Completed

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Recruiting

OpiCapone Effect on Motor Fluctuations and pAiN (OCEAN)

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites

Parkinson's Disease (PD)

Netherlands
Bial - Portela C S.A.

Completed

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

Parkinson Disease

United States
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites

Parkinson Disease

Switzerland
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment

Parkinson's Disease

France, Russian Federation
Bial - Portela C S.A.

Completed

Relative Bioavailability and Bioequivalence of Opicapone

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation

Epilepsy
Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone

Parkinson Disease

Germany
Bial - Portela C S.A.

Completed

Effect of Food on Opicapone

Parkinson Disease
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects

Parkinson Disease

France
Bial - Portela C S.A.

Completed

Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules

Parkinson

Canada
Galderma R&D

Completed

Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses (COMET2)

Actinic Keratoses

Spain, France, Germany, Netherlands, Sweden
Bial - Portela C S.A.

Active, not recruiting

OpicApone Sleep dISorder (OASIS)

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects

Parkinson Disease

France
NEURALIS s.a.

Active, not recruiting

Estetrol (E4) for the Treatment of Patients With Confirmed SARS-COV-2 Infection

Covid19

Belgium, Hungary, Russian Federation, Poland
Pfizer

Completed

A Study Of CP-690,550 In Stable Kidney Transplant Patients

Kidney Transplant

United States
Bial R&D Investments, S.A.

Recruiting

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE)

Parkinson's Disease

United States, Spain, France, Italy, Netherlands, United Kingdom, Germany, Canada, Poland, Portugal, Sweden
Estetra

Completed

Safety, Tolerability and Pharmacokinetics of Estetrol (E4) After Single and Multiple Oral Doses in Healthy Female Volunteers

Menopause | Contraception

Bulgaria
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity

Obesity | Overweight
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

Spain, United States, Netherlands, United Kingdom
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067

Parkinson's Disease (PD)

France
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Effect of Opicapone at Steady State on Warfarin Pharmacokinetics

Parkinson's Disease
Onconic Therapeutics Inc.

Not yet recruiting

Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers

Peptic Ulcer

Korea, Republic of
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF)

Non Small Cell Lung Cancer | BRAF V600E

France
National Cancer Center, Japan
Ono Pharmaceutical Co. Ltd

Recruiting

Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume) (Perfume)

Pancreatic Cancer | Low-grade Glioma

Japan
Fulcrum Therapeutics

Completed

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

Healthy Adult Subjects

United States
Quark Pharmaceuticals

Terminated

Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Non Arteritic Anterior Ischemic Optic Neuropathy

United States, Australia, Germany, China, India, Italy, Singapore, Israel
Corporacion Parc Tauli

Completed

Effects of Bupivacaine and Levobupivacaine on Cerebral Oxygenation During Intrathecal Anesthesia in Elderly Patients

Complication of Anesthesia

Spain
AstraZeneca

Active, not recruiting

A Study of CIN-107 in Adults With Primary Aldosteronism

Primary Aldosteronism | Hyperaldosteronism

United States
Dr. Reddy's Laboratories Limited

Completed

Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches

Migraine

United States
Jiaxing AnDiCon Biotech Co.,Ltd

Recruiting

ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection (ADC)

Safety Issues | Effect of Drug

China
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Recruiting

A Study of TG103 Injection in Overweight or Obesity

Overweight or Obesity

China
GlaxoSmithKline

Completed

PK Study of IV Formulation of GW856553

Cardiovascular Disease

United Kingdom
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

Parkinson Disease

Portugal
GlaxoSmithKline

Completed

A New Oral Treatment For Type II Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Germany, Canada, Sweden, Latvia, Finland, Greece, Romania, Czechia, Puerto Rico
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

Parkinson's Disease

Switzerland
Merck Sharp & Dohme LLC

Terminated

To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Anemia | Bladder Cancer | Cancer of Head and Neck | Uterine Cervical Cancer | Carcinoma, Small-Cell Lung
Nymox Corporation

Completed

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Prostate Cancer

United States

Search clinical trials for: BIA 9-1067 15 mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations